VA Ann Arbor Healthcare System, Ann Arbor, MI

Summary

VA Ann Arbor Healthcare System, Ann Arbor, MI is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Lung Cancer, Prostate Cancer, Diabetes, Post-Traumatic Stress Disorder, Cardiovascular Disease and other specialties. VA Ann Arbor Healthcare System, Ann Arbor, MI is involved with conducting 254 clinical trials across 335 conditions. There are 24 research doctors associated with this hospital, such as Michelle Mierzwa, M.D., David Elliott, Nithya Ramnath, MBBS, and Paul N Pfeiffer, MD MS.

Top PIs

Clinical Trials running at VA Ann Arbor Healthcare System, Ann Arbor, MI

Prostate Cancer

Lung Cancer

Cancer

Parkinson's Disease

Chronic Pain

Colorectal Cancer

Acute Viral Respiratory Infection

Suicide Prevention

Suicide Attempt

Post-Traumatic Stress Disorder

Docetaxel + Hormone Therapy

for Prostate Cancer

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

Recruiting

2 awards

Phase 3

5 criteria

Pembrolizumab

for Prostate Cancer

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.

Recruiting

2 awards

Phase 2

3 criteria

Systemic + Local Therapy

for Prostate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

Recruiting

1 award

Phase 2 & 3

3 criteria